Item 8.01 - Other Events.
On
As the Company works to finalize its evaluation of an additional Phase 3 clinical trial, it will continue the process to review potential strategic alternatives with the goal of maximizing shareholder value.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
This Current Report on Form 8-K contains forward-looking statements, including,
but not limited to, statements regarding the Company's plans to continue the
process to review potential strategic alternatives with the goal of maximizing
shareholder value, which are based on the Company's current expectations and
inherently involve significant risks and uncertainties. The Company's actual
results and the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of these risks and uncertainties,
including the risk that the Company may not be successful in identifying one or
more strategic alternatives or ultimately pursuing a strategic alternative that
delivers the anticipated benefits or enhances shareholder value, among other
risks and uncertainties. A further description of the risks and uncertainties
relating to the business of the Company is contained in the Company's most
recent annual report on Form 10-K and the Company's quarterly reports on Form
10-Q, as well as any amendments thereto reflected in subsequent filings with the
--------------------------------------------------------------------------------
© Edgar Online, source